Leading French Healthcare Facility Adopts an
Innovative Telemonitoring Platform as Part of a Mobile Neonatology
Unit for the Monitoring of Premature Newborns, Serving Both
Patients and Caregivers
Masimo (NASDAQ: MASI) today announced that Saint-Denis Hospital
Center is adopting the use of the Masimo SafetyNet® cloud-based
telemonitoring platform as part of an experimental mobile
neonatology unit aimed at facilitating earlier discharge of
premature newborns from the ICU to the home. Launched in February,
this pioneering project allows vulnerable neonates to return home
safely to their families while remaining under the close
supervision of the hospital.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240908136612/en/
Masimo SafetyNet® and Saint-Denis
Hospital Center, Delafontaine (France) (Photo: Business Wire)
Masimo SafetyNet offers a streamlined approach to remote patient
management that can be scaled and tailored to each patient’s unique
care needs, offering wireless continuous monitoring and spot-check
devices, customizable CarePrograms™ with symptom reporting, and a
secure in-hospital clinical portal that allows care teams to keep
watch over a large volume of patients. Following discharge,
families are sent home with an easy-to-use pulse oximetry sensor,
Radius PPG®, powered by clinically proven Masimo Signal Extraction
Technology® (SET®), and an intuitive smartphone application. The
sensor, worn on the foot of neonatal patients, includes a chip that
sends health data to the app, where parents can keep an eye on
their baby’s condition and communicate with caregivers. From the
hospital, caregivers receive that same data as well as notification
logs about changes in a patient’s condition—enabling them to
prioritize those who may need care escalation.
Staff members at Saint Denis were already familiar with the
benefits of home-based care. Dr. Pascal Bolot, head of neonatal
intensive care at Saint-Denis, first implemented home visits in
partnership with the ARS, a regional health authority, to address
the lack of care following hospital discharge and alleviate the
distress of the abrupt shift from hospital to home for families.
Saint-Denis’ experience providing home visits was a key advantage
when it came to implementing remote neonatal monitoring, alongside
11 other French facilities taking part in the trial. With the
integration of Masimo SafetyNet, the pilot has expanded its
approach to be more comprehensive and innovative – an approach
that, according to Dr. Alizée Lori, the pediatrician at Saint-Denis
who oversees the mobile unit, “[brings] premature newborns into a
secure home environment equivalent to hospital-grade monitoring
quality.” The addition of this technology serves as an opportunity
to “put the premature newborn back in the center of the family,”
added Dr. Bolot.
The mobile neonatology unit benefits caregivers and families
alike. As a general rule, neonatology services do not allow
premature babies to return home before the end of 36 weeks of
corrected age. Masimo SafetyNet may help make it possible to secure
an earlier return home, serving as a relay between hospital staff
and families and providing comprehensive support for premature
babies in their first few weeks of life. The success of this
program could lead to the deployment of Masimo SafetyNet in other
care areas, particularly in pediatric care, including home patient
management of various conditions.
Dr. Lori commented, “We chose this Masimo solution because of
its innovative nature and the practical aspect of wireless
physiological data monitoring; it’s easy for families to use and
gives our medical team easy access to patients’ health data from
the hospital. Since Masimo is used in many neonatology departments,
including CH Delafontaine, we were confident in the reliability of
the data recorded. This solution allows us to adapt care protocols
to meet the needs of our vulnerable patients. Additionally, the
Masimo team has supported us since the beginning of the project,
and is still available on a daily basis.”
The Saint-Denis Hospital Center, made up of the Delafontaine and
Casanova sites, is the only public healthcare facility in the
Plaine Commune area, serving a population of 435,000 people. The
facility offers 839 hospital beds with adult, pediatric and
gynecological emergency services, a large consultation platform,
and a type 3 perinatal center for monitoring high-risk pregnancies
through high-quality maternal and neonatal care for mothers and
children.
Joe Kiani, Founder and CEO of Masimo, said, “Our mission from
the beginning has been to improve patient outcomes and reduce cost
of care by taking noninvasive monitoring to new sites and
applications. And it’s incredible to see how far we’ve come. To see
parents be able to be with their newborn baby and each other is
extremely gratifying, and to help the dedicated team at Saint-Denis
provide earlier discharge yet keep the same level of monitoring is
something we’re all proud of. Masimo has long fought to protect
vulnerable newborns through innovative continuous monitoring, and
it is truly rewarding to see how Masimo SafetyNet—using the same
technology we’ve developed and perfected over 35 years—is helping
Saint-Denis extend comprehensive care to neonatal patients at home.
As healthcare becomes more predictive, preventative, and
personalized than ever before, we are committed to innovating
solutions that put patients at the center of the care
ecosystem.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.1
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,2 improve CCHD screening in
newborns,3 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.4-7 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,8 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked
in the 2024 Newsweek World’s Best Hospitals listing.9 In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013,
Masimo introduced the Root® Patient Monitoring and Connectivity
Platform, built from the ground up to be as flexible and expandable
as possible to facilitate the addition of other Masimo and
third-party monitoring technologies; key Masimo additions include
Next Generation SedLine® Brain Function Monitoring, O3® Regional
Oximetry, and ISA™ Capnography with NomoLine® sampling lines.
Masimo’s family of continuous and spot-check monitoring Pulse
CO-Oximeters® includes devices designed for use in a variety of
clinical and non-clinical scenarios, including tetherless, wearable
technology, such as Radius-7®, Radius PPG®, and Radius VSM™,
portable devices like Rad-67®, fingertip pulse oximeters like
MightySat® Rx, and devices available for use both in the hospital
and at home, such as Rad-97® and the Masimo W1® Medical Watch.
Masimo hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
Masimo W1 Sport. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website. Comparative studies
include independent and objective studies which are comprised of
abstracts presented at scientific meetings and peer-reviewed
journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar.
- Estimate: Masimo data on file.
-
https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet®, Masimo
Radius PPG®, and Masimo SET® and the implementation of Masimo
SafetyNet in Saint-Denis Hospital Center (the “Implementation”).
These forward-looking statements are based on current expectations
about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo’s unique noninvasive measurement
technologies, including Masimo SafetyNet, Masimo Radius PPG, and
Masimo SET®, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; risks related to our belief of the success of the
Implementation and that such success could lead to the deployment
of Masimo SafetyNet in other areas; risks related to COVID-19; as
well as other factors discussed in the “Risk Factors” section of
our most recent reports filed with the Securities and Exchange
Commission (“SEC”), which may be obtained for free at the SEC’s
website at www.sec.gov. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All
forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today’s date. We
do not undertake any obligation to update, amend or clarify these
statements or the “Risk Factors” contained in our most recent
reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240908136612/en/
Media Contact: Masimo Evan Lamb 949-396-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Nov 2023 to Nov 2024
